Scancell at H.C. Wainwright conference: melanoma vaccine nears phase III

Scancell plans to begin a 550-patient global phase III trial of melanoma vaccine iSCIB1+ in late 2026 after phase II data showed 77% progression-free survival at 22 months, versus 43% in the historical CheckMate 067 Ipilimumab/Nivolumab comparator. The planned Neuphoria Therapeutics merger is expected to provide $95 million of capitalization, a Nasdaq listing and cash runway through early 2029, covering the anticipated late-2028 to early-2029 interim readout. The investment case remains high-risk because the company must reproduce uncontrolled phase II results in a randomized pivotal study; SCLP is down about 66% from its $0.39 52-week high and trades near its lows.

Analysis

SCLP's valuation hinges on an unusually large efficacy gap derived from a non-randomized historical comparison, not on a contemporaneous control. That creates substantial regression-to-the-mean risk when the registrational study enrolls across 90 sites and incorporates biomarker selection; the key question is whether the control arm performs materially better than legacy benchmarks. The adaptive design reduces statistical failure risk but can extend duration, increase cash burn and leave equity holders exposed to financing before a confirmatory outcome.

The proposed NEUP transaction is the nearer-term equity catalyst, but its practical value depends on closing terms, pro forma float, redemption mechanics and the amount of cash actually delivered—not headline capitalization. A Nasdaq listing can broaden specialist-biotech ownership, yet it also creates a more liquid vehicle for arbitrage and post-close selling. Until a filed proxy/S-4 verifies ownership dilution, net cash and any contingent financing, SCLP should be treated as a merger-dependent microcap rather than a funded late-stage asset.

MRK and MRNA benefit more broadly from clinical validation of vaccine-plus-checkpoint combinations, but SCLP's off-the-shelf approach could become strategically relevant if it demonstrates durable benefit without added immune toxicity. The overlooked constraint is commercial: frontline advanced melanoma is already concentrated in immuno-oncology centers, so an additive therapy must show survival, not merely PFS, durability to earn meaningful uptake and reimbursement. GMAB's optionality is indirect through its partnered programs; it is not a material earnings catalyst over the next 12 months.

Near-term sentiment can improve on merger completion, enrollment and subsequent mature follow-up, but the principal value inflection is 24-30 months away. Falsifiers are a delayed close, net cash below expectations, slow enrollment, a control-arm PFS above assumptions, or lack of supportive OS trend at interim review. The calendar inconsistency around an allegedly future ESMO presentation also warrants source verification before underwriting any read-through from MRK/MRNA data.

Key Decisions for Investors

• Do not initiate a core SCLP position before NEUP closing documents disclose pro forma ownership, minimum cash, redemption exposure and lock-up terms. Reassess only if verified net cash provides at least 24 months of runway after transaction expenses and the stock trades near or below pro forma net cash plus a modest platform premium.
• For event-risk capital only, consider a small SCLP/NEUP merger-completion position after definitive filings, sized at 25-50 bps NAV maximum. Target a 2x upside on successful close/listing and enrollment execution; hard exit on closing delay, material cash shortfall, or dilution exceeding filed assumptions.
• Maintain MRK as the lower-volatility immuno-oncology exposure rather than chasing SCLP on platform-validation headlines. Any vaccine-combination success is strategically supportive but too immaterial to near-term MRK earnings to justify a standalone catalyst trade.
• Watch SCLP's first-half 2027 mature follow-up for patient-level durability, OS trend, baseline-risk balance and biomarker-subgroup consistency. A durable advantage across poor-prognosis subgroups would justify upgrading to a longer-dated clinical-event position; selective or diminishing benefit would support avoiding the name despite phase III progress.
• Monitor GMAB only for disclosed milestone economics or advancement of partnered glycan assets; absent explicit payments or pipeline prioritization, the financial read-through is insufficient for a trade.